Inogen (Nasdaq: INGN) adds COO Andy Reding with equity package
Rhea-AI Filing Summary
Inogen, Inc. is creating a new Chief Operating Officer role and has appointed Andy Reding, effective July 6, 2026. He will oversee revenue, operations, and cross-functional execution as the company pursues new products and geographic expansion in respiratory care.
Reding’s employment agreement provides a $500,000 annual base salary, a target bonus equal to 70% of salary, and a $100,000 cash sign-on bonus, partially repayable if he departs under certain conditions within two years. Inogen will also reimburse $2,500 of his legal fees related to the agreement.
As an equity inducement, Reding will receive 130,000 time-based RSUs, vesting in three equal annual installments, granted outside existing equity plans under Nasdaq Listing Rule 5635(c)(4). If he is terminated without cause or resigns for good reason, he may receive salary continuation and subsidized medical benefits for 12 months, or 24 months if this occurs around a change of control, subject to a release of claims and other conditions.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
restricted stock units financial
change of control financial
Nasdaq Stock Market Rule 5635(c)(4) regulatory
Regulation FD regulatory
Section 280G of the Internal Revenue Code financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
|
|
(Former address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Chief Operating Officer
On June 2, 2026, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer (“COO”) of the Company, effective July 6, 2026.
Mr. Reding, 56, served as Chief Commercial Officer of Viant Medical from September 2020 to March 2026 where he led the commercial function and teams supporting complex medical device design and manufacturing programs. Prior to joining Viant Medical, Mr. Reding served as Vice President and General Manager at Hillrom Respiratory Health from 2015 to 2020. Prior to that, he held a variety of senior leadership roles at Trumpf Medical Systems, which was acquired by Hillrom. Mr. Reding received a masters degree in business and administration from the University of South Carolina and a bachelor’s degree in business administration and English from Marquette University.
On June 2, 2026, the Board, upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved, and the Company entered into, an employment and severance agreement with Mr. Reding (the “employment agreement”), effective July 6, 2026 (the “Effective Date”). Mr. Reding’s employment under the employment agreement will begin on the Effective Date and is at will and may be terminated at any time by the Company or by Mr. Reding. Pursuant to the employment agreement, Mr. Reding will receive an annual base salary of $500,000 and a target annual performance bonus opportunity of seventy percent (70%) of his annual base salary. The employment agreement provides for a cash sign-on bonus of $100,000, which is repayable on a pro-rata basis if, prior to the second anniversary of the Effective Date, Mr. Reding’s employment is terminated by the Company for cause or Mr. Reding resigns without good reason (in each case as defined in the employment agreement). In addition, the employment agreement provides that the Company will pay Mr. Reding $2,500 within thirty (30) days of the Effective Date to cover legal fees incurred in connection with entry into the employment agreement.
The employment agreement also provides for an equity award of time-based restricted stock units (“RSUs”) covering 130,000 shares of the Company’s common stock. Subject to Mr. Reding’s continued service with the Company, one-third of the RSUs will vest annually over three years.
The RSUs will be granted on the Effective Date and are subject to the terms and conditions of the related award agreement. The RSUs will be granted as independent inducement awards outside of the terms of the Company’s existing equity incentive plans in compliance with an exemption from Nasdaq’s shareholder approval requirements under Nasdaq Stock Market Rule 5635(c)(4).
The employment agreement also provides that Mr. Reding will be eligible to receive equity awards pursuant to any plans or arrangements that the Company may have in effect from time to time, and as approved by the Board or the Compensation Committee.
Mr. Reding’s employment agreement also provides that if, outside of the period beginning on the date three months before, and ending on the date 12 months following, a change of control (as defined in the employment agreement) (such period, the “change of control period”), his employment with the Company is terminated by the Company without cause (excluding by reason of death or disability) or he resigns for good reason, he will be eligible to receive the following severance benefits:
The employment agreement further provides that if, during the change of control period, Mr. Reding’s employment with the Company is terminated by the Company without cause (excluding by reason of death or disability) or he resigns for good reason, he will be eligible to receive the same severance benefits described above, except that he will receive continued payment of his base salary for a period of 24 months following his termination date.
Mr. Reding’s receipt of the severance benefits described above is conditioned on his timely signing and not revoking a release of claims, resigning all directorships, committee memberships or any other positions he holds with the Company, and continuing to comply with certain covenants in the employment agreement and in his confidential information, invention assignment, and arbitration agreement with the Company.
If any of the payments provided for under the employment agreement or otherwise payable to Mr. Reding would constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code (the “Code”) and would be subject to the related excise tax under Section 4999 of the Code, then he will be entitled to receive either full payment of benefits or such lesser amount that would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of after-tax benefits to him.
The summary of Mr. Reding’s employment agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the employment agreement, which is filed with this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference herein.
In addition, Inogen has entered into its standard form of indemnification agreement with Mr. Reding. The form indemnification
agreement was filed with the Securities and Exchange Commission on November 27, 2013 as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 and is incorporated herein by reference. Mr. Reding has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor are any such transactions currently proposed. There is no arrangement or understanding between Mr. Reding or any other person pursuant to which Mr. Reding was selected as an officer. There are no family relationships between Mr. Reding and any of the Company’s directors or executive officers.
Item 7.01. Regulation FD Disclosure.
On July 1, 2026, the Company issued a press release announcing the Chief Operating Officer appointment described in this Current Report on Form 8-K. A copy of the press release is furnished herewith as Exhibit 99.1.
The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
Description |
|
|
|
10.1 |
|
Employment and Severance Agreement by and between the Company and Andrew Reding, effective as of July 6, 2026. |
99.1 |
|
Press Release dated July 1, 2026. |
104 |
|
The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
INOGEN, INC. |
|
|
|
|
Date: |
July 1, 2026 |
By: |
/s/ Jason Richardson |
|
|
|
Jason Richardson |
Exhibit 99.1
|
|
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Newly created role strengthens leadership structure to support Inogen’s global commercial and operational execution
BEVERLY, Mass., July 1, 2026 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Andy Reding to the newly created role of Chief Operating Officer, effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen’s strategy is translated into efficient and measurable outcomes.
“As we continue to diversify Inogen’s business through new product launches and geographic expansion, we are streamlining our leadership structure to enhance execution and accelerate delivery of our strategic priorities,” said Kevin Smith, Inogen’s Chief Executive Officer. “Andy’s deep experience building high-performing teams and scaling complex medical technology businesses will be invaluable as we continue to drive top-line growth, advance profitability and expand the innovation pipeline.”
“I am honored to join Inogen at such an important time in the company’s evolution,” said Andy Reding. “Inogen has a strong foundation, a compelling mission, and significant opportunities to expand its impact for patients and providers globally. I look forward to working with Kevin and the broader team to transform Inogen into a global respiratory care leader.”
Mr. Reding joins Inogen with more than 30 years of leadership experience across medical technology, commercial operations, product development, and healthcare reimbursement. Most recently, he served as Chief Commercial Officer of Viant Medical, where for more than six years he led teams supporting complex medical-device design and manufacturing programs. Across 25 facilities, Viant serves hundreds of medical device companies, including the top companies in the world, and experienced exceptional growth during his tenure.
Mr. Reding has extensive respiratory care experience as he served as Vice President and General Manager of Hillrom Respiratory Health, where he led sales, marketing, customer service, research and development, reimbursement, and third-party billing. During his tenure, his team expanded the sales force, developed new products, and successfully navigated FDA and CMS requirements to bring innovative products to market.
Mr. Reding holds a Master of Business Administration from the University of South Carolina and a bachelor’s degree from Marquette University.
In connection with entering into employment with Inogen, Mr. Reding will receive an inducement equity award of restricted stock units (“RSUs”) covering an aggregate of 130,000 shares of Inogen’s common stock. Subject to Mr. Reding’s continued service with Inogen, one-third of the RSUs will vest annually over three years. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.
For more information, please visit www.inogen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to Inogen’s 2026 full year financial guidance; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2025, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Contact
ir@inogen.net